Celcuity Inc.

CELC· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$84.91+2.82%

2026-09-17

Financials

Valuation Metrics

Celcuity Inc.'s Market Cap is $4.14B. At end of 2025 it was $5.24B. Ranked #1501 of 3,121 in US market (top 48%), #522 of 1,463 on NASDAQ (top 36%), #90 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$4.14B	US#1,501/3,121 Sec#90/266
Revenue	$0.00	US#2,889/3,121 Sec#196/266
Net Income	$-226M	US—/3,121 Sec—/266
Total Assets	$828M	US#2,559/3,121 Sec#117/266
Net Assets	$-13M	US#2,933/3,121 Sec#246/266
Employees	155	US#2,541/3,121 Sec#144/266
Value
FCF Yield	-4.64%	US—/3,121 Sec—/266
Profitability
ROA	-27.35%	US#2,868/3,121 Sec#149/266
Financial Health
Total Debt	$754M	US#1,686/3,121 Sec#54/266
FCF	$-192M	US#2,771/3,121 Sec#204/266
Cash	$182M	US#1,810/3,121 Sec#118/266
Current Ratio	8.93x	US#293/3,121 Sec#88/266
Performance
1Y Return	55.51%	US#509/3,121 Sec#99/266
1M Return	-8.93%	US#2,327/3,121 Sec#175/266
From 52W High	-43.78%	US#2,563/3,121 Sec#204/266
1Y MDD	-43.25%	US#2,174/3,121 Sec#154/266
Trading
Volume	675,696 shares	US#1,734/3,121 Sec#185/266
Trading Value	$58M	US#1,167/3,121 Sec#87/266
Per Share
EPS	$-4.64	US—/3,121 Sec—/266
BPS	$-0.26	US—/3,121 Sec—/266

Company Info

CEO Brian F. Sullivan

Employees 155

HQ Minneapolis, US

Website https://www.celcuity.com

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.